Mutated cancer autoantigen implicated cause of paraneoplastic myasthenia gravis

Anastasia Zekeridou, Guy E. Griesmann, Vanda A Lennon

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction: Antitumor immune responses are postulated to initiate paraneoplastic neurological disorders when proteins that are normally restricted to neural cells are expressed as oncoproteins. Mutated oncopeptides could bypass self-tolerant T cells to activate cytotoxic effector T lymphocytes and requisite helper T lymphocytes to stimulate autoantibody production by B lymphocytes. Methods: We investigated muscle-type nicotinic acetylcholine receptor (AChR) antigen expression at transcriptional and protein levels in a small-cell lung cancer line (SCLC) established from a patient with AChR-immunoglobulin G (IgG)-positive myasthenia gravis. Results: We identified messenger RNA transcripts encoding the 2 AChR α1-subunit isoforms and 7 alternative-splicing products, 3 of which yielded premature stop codons. Despite detecting native muscle-type AChR pentamers in the tumor, we did not identify mutant α1-peptides. However, we found α1-subunit-derived peptides bound to tumor major histocompatibility complex (MHC)1-protein. In a control SCLC from an antineuronal nuclear autoantibody, type 1 (anti-Hu)-IgG-positive patient, we identified MHC1-complexed Hu protein-derived peptides but not AChR peptides. Discussion: Our findings support onconeural protein products as pertinent immunogens initiating paraneoplastic neurological autoimmunity. Muscle Nerve, 2018.

Original languageEnglish (US)
JournalMuscle and Nerve
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Myasthenia Gravis
Autoantigens
Cholinergic Receptors
Peptides
Small Cell Lung Carcinoma
Neoplasms
Proteins
Muscles
Autoantibodies
Immunoglobulin G
Nonsense Codon
Oncogene Proteins
Alternative Splicing
Nicotinic Receptors
Cytotoxic T-Lymphocytes
Helper-Inducer T-Lymphocytes
Nervous System Diseases
Major Histocompatibility Complex
Autoimmunity
Protein Isoforms

Keywords

  • cancer neoantigen
  • lung cancer
  • muscle acetylcholine receptor autoantibody
  • onconeural antigens
  • paraneoplastic autoimmunity
  • sensory neuronopathy

ASJC Scopus subject areas

  • Physiology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)

Cite this

Mutated cancer autoantigen implicated cause of paraneoplastic myasthenia gravis. / Zekeridou, Anastasia; Griesmann, Guy E.; Lennon, Vanda A.

In: Muscle and Nerve, 01.01.2018.

Research output: Contribution to journalArticle

@article{14bb90ed87ee4faab99f9bb3eb8d822a,
title = "Mutated cancer autoantigen implicated cause of paraneoplastic myasthenia gravis",
abstract = "Introduction: Antitumor immune responses are postulated to initiate paraneoplastic neurological disorders when proteins that are normally restricted to neural cells are expressed as oncoproteins. Mutated oncopeptides could bypass self-tolerant T cells to activate cytotoxic effector T lymphocytes and requisite helper T lymphocytes to stimulate autoantibody production by B lymphocytes. Methods: We investigated muscle-type nicotinic acetylcholine receptor (AChR) antigen expression at transcriptional and protein levels in a small-cell lung cancer line (SCLC) established from a patient with AChR-immunoglobulin G (IgG)-positive myasthenia gravis. Results: We identified messenger RNA transcripts encoding the 2 AChR α1-subunit isoforms and 7 alternative-splicing products, 3 of which yielded premature stop codons. Despite detecting native muscle-type AChR pentamers in the tumor, we did not identify mutant α1-peptides. However, we found α1-subunit-derived peptides bound to tumor major histocompatibility complex (MHC)1-protein. In a control SCLC from an antineuronal nuclear autoantibody, type 1 (anti-Hu)-IgG-positive patient, we identified MHC1-complexed Hu protein-derived peptides but not AChR peptides. Discussion: Our findings support onconeural protein products as pertinent immunogens initiating paraneoplastic neurological autoimmunity. Muscle Nerve, 2018.",
keywords = "cancer neoantigen, lung cancer, muscle acetylcholine receptor autoantibody, onconeural antigens, paraneoplastic autoimmunity, sensory neuronopathy",
author = "Anastasia Zekeridou and Griesmann, {Guy E.} and Lennon, {Vanda A}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/mus.26166",
language = "English (US)",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Mutated cancer autoantigen implicated cause of paraneoplastic myasthenia gravis

AU - Zekeridou, Anastasia

AU - Griesmann, Guy E.

AU - Lennon, Vanda A

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Introduction: Antitumor immune responses are postulated to initiate paraneoplastic neurological disorders when proteins that are normally restricted to neural cells are expressed as oncoproteins. Mutated oncopeptides could bypass self-tolerant T cells to activate cytotoxic effector T lymphocytes and requisite helper T lymphocytes to stimulate autoantibody production by B lymphocytes. Methods: We investigated muscle-type nicotinic acetylcholine receptor (AChR) antigen expression at transcriptional and protein levels in a small-cell lung cancer line (SCLC) established from a patient with AChR-immunoglobulin G (IgG)-positive myasthenia gravis. Results: We identified messenger RNA transcripts encoding the 2 AChR α1-subunit isoforms and 7 alternative-splicing products, 3 of which yielded premature stop codons. Despite detecting native muscle-type AChR pentamers in the tumor, we did not identify mutant α1-peptides. However, we found α1-subunit-derived peptides bound to tumor major histocompatibility complex (MHC)1-protein. In a control SCLC from an antineuronal nuclear autoantibody, type 1 (anti-Hu)-IgG-positive patient, we identified MHC1-complexed Hu protein-derived peptides but not AChR peptides. Discussion: Our findings support onconeural protein products as pertinent immunogens initiating paraneoplastic neurological autoimmunity. Muscle Nerve, 2018.

AB - Introduction: Antitumor immune responses are postulated to initiate paraneoplastic neurological disorders when proteins that are normally restricted to neural cells are expressed as oncoproteins. Mutated oncopeptides could bypass self-tolerant T cells to activate cytotoxic effector T lymphocytes and requisite helper T lymphocytes to stimulate autoantibody production by B lymphocytes. Methods: We investigated muscle-type nicotinic acetylcholine receptor (AChR) antigen expression at transcriptional and protein levels in a small-cell lung cancer line (SCLC) established from a patient with AChR-immunoglobulin G (IgG)-positive myasthenia gravis. Results: We identified messenger RNA transcripts encoding the 2 AChR α1-subunit isoforms and 7 alternative-splicing products, 3 of which yielded premature stop codons. Despite detecting native muscle-type AChR pentamers in the tumor, we did not identify mutant α1-peptides. However, we found α1-subunit-derived peptides bound to tumor major histocompatibility complex (MHC)1-protein. In a control SCLC from an antineuronal nuclear autoantibody, type 1 (anti-Hu)-IgG-positive patient, we identified MHC1-complexed Hu protein-derived peptides but not AChR peptides. Discussion: Our findings support onconeural protein products as pertinent immunogens initiating paraneoplastic neurological autoimmunity. Muscle Nerve, 2018.

KW - cancer neoantigen

KW - lung cancer

KW - muscle acetylcholine receptor autoantibody

KW - onconeural antigens

KW - paraneoplastic autoimmunity

KW - sensory neuronopathy

UR - http://www.scopus.com/inward/record.url?scp=85053209026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053209026&partnerID=8YFLogxK

U2 - 10.1002/mus.26166

DO - 10.1002/mus.26166

M3 - Article

C2 - 29742813

AN - SCOPUS:85053209026

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

ER -